ABT Aqua Bio Technology

Aqua Bio Technology (ABT) buys all rights to Moana Skincare and integrates backwards into the value chain.

Aqua Bio Technology (ABT) buys all rights to Moana Skincare and integrates backwards into the value chain.

ABT has been a distributor of products from Moana Skincare since 2017 and has had exclusive distribution rights in Europe, the Middle East and Africa. ABT now acquires all rights to Moana Skincare and integrates backwards in the value chain. The acquisition gives ABT control over the entire value chain from production to global distribution. ABT will maintain its local presence and knowledge by entering into an agreement with Moana Skincare New Zealand Limited for the distribution of the products in New Zealand and Australia. Through the acquisition, ABT further develops and strengthens its position as a supplier and distributor of certified organic and natural skin care products, and ABT expects to realize synergies through the utilization of its own and new market access.

Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled nature. These have been used in traditional medicine by the country's indigenous people, the Maori, for centuries. The cornerstone of Moana Skincare's skin care products is a certified organic red algae found only in the waters around New Zealand. The products have a documented moisturizing effect that lasts for a full 60 hours after application on the skin, which is several times better than the competitors on the market. The series is also organically certified according to one of the world's strictest standards. See the appendix for a more detailed description of today's certified organic and natural skin care products from Moana Skincare.

ABT will pay up to NOK 26.7 million for the rights to Moana Skincare with three initial payments (NZD 500,000, NZD 250,000 and NZD 215 000) of approximately NOK 5.8 million (NZD 965,000) and a turnover-based payment of up to appr. NOK 20.6 million (Euro 1,95 million) based on a turnover for ABT of up to appr. NOK 211 million (Euro 20 million). In addition, ABT will pay a royalty of net sales the first 5 years. The positive financial consequences of the acquisition will be significant in the event of successful revenue growth.

- The acquisition of the rights to Moana Skincare fits very well into our strategy of developing, marketing and selling natural products. Getting quality products like Moana Skincare, which also holds an organic certification, into our portfolio is another part of our goal of offering natural products to the global cosmetics market. The company's board and management also have high expectations that we will develop even more products that will benefit both existing and new customers and distributors. The acquisition also brings opportunities in Moana Skincare's already existing market in the Pacific region, so there is also a good basis for creating further synergies. The acquisition of Moana Skincare's rights is part of ABT's focus on global commercialization and development of natural ingredients and natural skin care products, says Espen Kvale, CEO of ABT.

For further information, please contact CEO Espen Kvale, telephone .

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on the Axess market of the Oslo Stock Exchange.

This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.

Attachment

EN
10/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aqua Bio Technology

 PRESS RELEASE

Aqua Bio Technology ASA: Safety studies of 6 products from the product...

Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approved Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approvedReference is made to the stock exchange announcement of regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. We have today received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 1...

 PRESS RELEASE

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produkts...

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produktserien Balance & Vitality fullført og godkjent Det vises til børsmelding av vedrørende pågående sikkerhetsstudier for produktseriene Nordic Beauty og Balance & Vitality. ABT har mottatt bekreftelse på at de 6 første produktene fra Balance & Vitality serien har passert sikkerhetsstudier som EU krever gjennomført før kommersialisering. Resultatene for ytterligere 18 produkter forventes i løpet av januar i 2021, mens de siste 3 produktene som kompletterer serien forventes godkjent i løpet av Q1. Balance & Vitality vil være e...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with...

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with Restorsea - Conversion Lab launches Veritas MD platform Restorsea's commercialization of Aqua Bio Technologies ASA's hatching fluid ingredient (Aquabeautine XL) continues. As mentioned in the commercial update on November 26, 2020, Restorsea has recently entered into two license agreements with two partners in addition to the license agreement with NASDAQ-listed Conversion Labs. In connection with Hydrafacial`s merger with Vesper Healthcare and the contemplated listing on (NASDAQ), Restorsea is presented as . In Q3 20...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restors...

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restorsea – Conversion Lab lanserer Veritas MD plattform Restorseas kommersialisering av Aqua Bio Technologys ASAs klekkeveskeingrediens (Aquabeautine XL) fortsetter. Som nevnt i kommersiell oppdatering 26. november 2020, har Restorsea nylig inngått to lisensavtaler med to partnere i tillegg til lisensavtalen med NASDAQ-noterte Conversion Labs. I forbindelse med Hydrafacial`s fusjon med Vesper Healthcare og den planlagte noteringen på (NASDAQ), presenteres Restorsea som . Hydrafacial opplyser at selskapet per Q3 2020 har utpl...

 PRESS RELEASE

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - dis...

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - distribution agreement for New Zealand and Australia close Reference is made to where it is informed that Aqua Bio Technology ASA (ABT) is acquiring all rights to Moana Skincare . This acquisition has now been completed and in the near future ABT expects to enter into a three-year agreement for the distribution of Moana products in New Zealand and Australia. Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled na...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch